Switch theme
Sign up to access all valuation multiples
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
2008
353
LTM Revenue $180M
LTM EBITDA -$101M
$256M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Regenxbio has a last 12-month revenue (LTM) of $180M and a last 12-month EBITDA of -$101M.
In the most recent fiscal year, Regenxbio achieved revenue of $83.3M and an EBITDA of -$198M.
Regenxbio expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Regenxbio valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $180M | XXX | $83.3M | XXX | XXX | XXX |
| Gross Profit | $147M | XXX | $49.8M | XXX | XXX | XXX |
| Gross Margin | 82% | XXX | 60% | XXX | XXX | XXX |
| EBITDA | -$101M | XXX | -$198M | XXX | XXX | XXX |
| EBITDA Margin | -56% | XXX | -238% | XXX | XXX | XXX |
| EBIT | -$138M | XXX | -$231M | XXX | XXX | XXX |
| EBIT Margin | -77% | XXX | -278% | XXX | XXX | XXX |
| Net Profit | -$139M | XXX | -$227M | XXX | XXX | XXX |
| Net Margin | -77% | XXX | -273% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Regenxbio's stock price is $9.
Regenxbio has current market cap of $444M, and EV of $256M.
See Regenxbio trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $256M | $444M | XXX | XXX | XXX | XXX | $-2.81 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Regenxbio has market cap of $444M and EV of $256M.
Regenxbio's trades at 3.1x EV/Revenue multiple, and -1.3x EV/EBITDA.
Equity research analysts estimate Regenxbio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Regenxbio has a P/E ratio of -3.2x.
See valuation multiples for Regenxbio and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $444M | XXX | $444M | XXX | XXX | XXX |
| EV (current) | $256M | XXX | $256M | XXX | XXX | XXX |
| EV/Revenue | 1.4x | XXX | 3.1x | XXX | XXX | XXX |
| EV/EBITDA | -2.5x | XXX | -1.3x | XXX | XXX | XXX |
| EV/EBIT | -1.9x | XXX | -1.1x | XXX | XXX | XXX |
| EV/Gross Profit | 1.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | -3.2x | XXX | -2.0x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -1.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialRegenxbio's last 12 month revenue growth is 66%
Regenxbio's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.8M for the same period.
Regenxbio's rule of 40 is -200% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Regenxbio's rule of X is 108% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Regenxbio and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 66% | XXX | 81% | XXX | XXX | XXX |
| EBITDA Margin | -56% | XXX | -238% | XXX | XXX | XXX |
| EBITDA Growth | -110% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -200% | XXX | -172% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 108% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.8M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 250% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 337% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Regenxbio acquired XXX companies to date.
Last acquisition by Regenxbio was XXXXXXXX, XXXXX XXXXX XXXXXX . Regenxbio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Regenxbio founded? | Regenxbio was founded in 2008. |
| Where is Regenxbio headquartered? | Regenxbio is headquartered in United States of America. |
| How many employees does Regenxbio have? | As of today, Regenxbio has 353 employees. |
| Who is the CEO of Regenxbio? | Regenxbio's CEO is Mr. Curran Simpson. |
| Is Regenxbio publicy listed? | Yes, Regenxbio is a public company listed on NAS. |
| What is the stock symbol of Regenxbio? | Regenxbio trades under RGNX ticker. |
| When did Regenxbio go public? | Regenxbio went public in 2015. |
| Who are competitors of Regenxbio? | Similar companies to Regenxbio include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Regenxbio? | Regenxbio's current market cap is $444M |
| What is the current revenue of Regenxbio? | Regenxbio's last 12 months revenue is $180M. |
| What is the current revenue growth of Regenxbio? | Regenxbio revenue growth (NTM/LTM) is 66%. |
| What is the current EV/Revenue multiple of Regenxbio? | Current revenue multiple of Regenxbio is 1.4x. |
| Is Regenxbio profitable? | Yes, Regenxbio is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Regenxbio? | Regenxbio's last 12 months EBITDA is -$101M. |
| What is Regenxbio's EBITDA margin? | Regenxbio's last 12 months EBITDA margin is -56%. |
| What is the current EV/EBITDA multiple of Regenxbio? | Current EBITDA multiple of Regenxbio is -2.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
